# Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

> **NCT02758730** · PHASE1 · WITHDRAWN · sponsor: **Affiris AG**

## Conditions studied

- Parkinson's Disease

## Interventions

- **BIOLOGICAL:** AFFITOPE® PD01A + Adjuvant
- **BIOLOGICAL:** Adjuvant without active component

## Key facts

- **NCT ID:** NCT02758730
- **Lead sponsor:** Affiris AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2017-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02758730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02758730, "Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02758730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*